Dr M H Emmelot-Vonk

Correspondence to: Dr M H Emmelot-Vonk, University Medical Center, Utrecht, The Netherlands; m.h.emmelotvonk@umcutrecht.nl

STUDY DESIGN

Design:

randomised, placebo controlled trial.

Allocation:

{concealed}*.†

Blinding:

blinded (participants and clinicians).†

STUDY QUESTION

Setting:

University Medical Centre in Utrecht, the Netherlands.

Patients:

237 men 60–80 years of age (mean age 67 y) who had testosterone concentrations <13.7 nmol/l (394.8 ng/dl). Exclusion criteria included myocardial infarction or cerebrovascular accident in the past 6 months; heart failure unless medically treated and not symptomatic; cancer in the past 5 years except non-melanoma skin cancer and hormone dependent tumor; renal or liver disease; haematological abnormalities; epilepsy or use of antiepileptic medication; >1 migraine per month; diabetes mellitus; fasting glucose concentration ⩾6.9 mmol/l (124 mg/dl); corticosteroid use (⩾7.5 mg/d in the past 6 mo except for prednisolone use …